Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14162295 | 0.73 | ALDH1A1 (0.46) | LMNACYP2D6TSHRCYP2C19MC4R | |
| SCHEMBL14162253 | 0.72 | ALDH1A1 (0.38) | RAB9ALMNATSHRMC4R | |
| SCHEMBL13541755 | 0.66 | P2RX7 (0.44) | ATMPOLBMC4R | |
| SCHEMBL14047581 | 0.66 | ALDH1A1 (0.45) | POLBRAB9ACYP3A4CYP2C19MC4R | |
| SCHEMBL4294474 | 0.66 | HPGD (0.63) | — | |
| SCHEMBL14162398 | 0.65 | HTT (0.45) | POLBTP53LMNAMC4R | |
| SCHEMBL3109722 | 0.65 | SRC (0.61) | SRCPOLBRAB9ATP53CYP1A2 | |
| SCHEMBL29699631 | 0.65 | SRC (0.61) | SRCPOLBRAB9ATP53CYP1A2 | |
| SCHEMBL14162622 | 0.65 | HPGD (0.50) | POLBTP53LMNACYP1A2CYP3A4 | |
| SCHEMBL28229572 | 0.64 | SRC (0.90) | SRCPOLBRAB9ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | CAYMAN CHEMICAL COMPANY (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, HPGD, GMDS | ATM 4860/4885SRC 4414/4885POLB 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.